BioAtla (NASDAQ:BCAB) Trading Down 1.7% – Should You Sell?

BioAtla, Inc. (NASDAQ:BCAB) shares were down 1.7% during mid-day trading on Friday . The stock traded as low as $3.89 and last traded at $3.9210. Approximately 6,513 shares were traded during trading, a decline of 89% from the average session volume of 60,562 shares. The stock had previously closed at $3.99.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BCAB. Wall Street Zen raised shares of BioAtla to a “hold” rating in a report on Saturday, April 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioAtla in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $200.00.

BioAtla Stock Performance

The firm has a 50 day simple moving average of $3.83 and a two-hundred day simple moving average of $8.32. The stock has a market cap of $6.50 million, a P/E ratio of -0.09 and a beta of 0.76.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Friday, May 15th. The company reported ($4.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.00) by $5.78.

Hedge Funds Weigh In On BioAtla

Several large investors have recently bought and sold shares of BCAB. Millennium Management LLC lifted its stake in shares of BioAtla by 123.4% in the 4th quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock worth $433,000 after acquiring an additional 421,072 shares during the period. Marshall Wace LLP acquired a new position in shares of BioAtla during the fourth quarter valued at approximately $508,000. Vanguard Group Inc. raised its holdings in BioAtla by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after purchasing an additional 162,647 shares in the last quarter. Acadian Asset Management LLC raised its holdings in BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in BioAtla in the fourth quarter worth approximately $104,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.